Armistice Capital’s Virax Biolabs VRAX Stock Holding History

Armistice Capital’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$193K	Buy	+35,152	New	+$216K	﹤0.01%	229
2024 Q1	–	Sell	-4,880	Closed	-$178K	–	415
2023 Q4	$178K	Buy	+4,880	New	+$285K	﹤0.01%	243
2023 Q2	–	Sell	-6,000	Closed	-$1.04M	–	269
2023 Q1	$1.04M	Buy	+6,000	New	+$1.17M	0.02%	139

Other funds holding VRAX

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Armistice Capital's VRAX Position: Q1 2026 in Review

Armistice Capital opened a new position in Virax Biolabs (VRAX) in Q1 2026: 35,152 shares worth $193K. The stake represents ﹤0.01% of the portfolio and ranks #229 among its holdings. This is a return to the name: Armistice Capital previously reported a position in VRAX as recently as Q4 2023.

Armistice Capital first reported a position in VRAX in Q1 2023 and has held it in 3 quarters since. The position peaked at $1.04M in Q1 2023. 4 funds tracked by Wall St. Rank hold VRAX as of Q1 2026.

Armistice Capital held 35,152 shares of Virax Biolabs worth $193K as of Q1 2026.
Virax Biolabs was a new Armistice Capital position in Q1 2026.
Virax Biolabs made up ﹤0.01% of Armistice Capital's portfolio in Q1 2026, its #229 holding.
Armistice Capital first reported a position in Virax Biolabs in Q1 2023 and has held it in 3 quarters since.
Armistice Capital's Virax Biolabs position peaked at $1.04M in Q1 2023.
4 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.